Mr. Richard Schnoor reports

VODIS PHARMACEUTICALS INC. CLOSES FINAL TRANCHE OF $226,000 OF NON-BROKERED PRIVATE PLACEMENT

Vodis Pharmaceuticals Inc. has closed the second and final tranche of a non-brokered private placement of $226,000 (2.26 million units), plus a shares for debt settlement of $186,835.20 (1,858,358 units), at a subscription price of 10 cents per unit. Each unit comprises one common share in the capital of the company. There is a four-month hold period expiring Aug. 14, 2015.

Due to better than expected investor interest, the initially announced $500,000 private placement was oversubscribed and closed with $686,000 in total gross proceeds. Otto Folprecht, chief executive officer and a director, states: "We are very pleased with continued shareholder and investor confidence, as reflected by the oversubscription in the private placement. Furthermore, the oversubscription is a testament to the management team, and the future plans for Vodis and the Vodis brand."

The proceeds of the private placement will be used for expansion opportunities in the United States and European markets, and for general working capital purposes.

The following insiders of the company participated in the private placement: Derek Good for 600,000 units; Mr. Folprecht for 188,652 units; and Brian Gusko, chief financial officer, for 150,000 units.

In connection with the financing, the company will pay to qualified recipients associated fees of 7 per cent in cash commission and 7 per cent in finder's warrants, or $7,070 and 70,700 finder's warrants. Finder's warrants are exercisable at 25 cents per share for a period of two years.

We seek Safe Harbor.